Abbott Laboratories (ABT): CEO exercised options on 247K shares
Robert B Ford, CEO at Abbott Laboratories, reported an option exercise of 247K shares.
- 247K
- Shares · @ $59.94
- Traded
- Aug 25, 2026
- Filed
- Aug 27, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
The company's last weighty Form 8-K report up to this date: reported its results, 40 days earlier (Jul 16, 2026). The first one after it: reported its results, 57 days later (Oct 21, 2026).
- CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- Congress · 1 personMembers of Congress: 2 purchases
- CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- FDAFDA device clearance: Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP Catheter
- Government · Federal Register proposed ruleMedicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
- CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- CongressDisclosed sale of ABT — reported range $15,001 - $50,000
- FDAFDA device clearance: EnSite X EP System
- Company filing · Form 8-K · ResultsReported its results
- CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- CongressDisclosed sale of ABT — reported range $1,001 - $15,000
- Government · Federal Register noticeForeign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
- InsiderOfficer sold ~$643K of ABT shares in the open market
- FDARecall: Fisher Scientific Sure-Vue Serum/Urine hCG, Model/ Part: FHC-202/23900529, FHC-202/23900528; Beckman Coulter Inc's ICON 25 hCG, Model/ Part: FHC-202/43025; Hen…
- FDARecall: McKesson CONSULT hCG Urine Cassette, Model/ Part: FHC-A102/5001; Alere hCG Cassette (20 mIU/mL) in Urine, Model/ Part: FHC-A102/92210; Fisher Scientific Sure-V…
- FDARecall: Fisher Scientific Sure-Vue Urine hCG Strip, Model/ Part: FHC-101/23900527; McKesson CONSULT hCG Urine Test Dipstick CLIA Waived, Model/ Part:FHC-101/5000; Henr…
- FDARecall: Fisher Scientific Sure-Vue Urine hCG, Model/ Part: FHC-102/23900526; Henry Schein, Inc. One Step + Urine Cassette Test, Model/ Part: FHC-102/9004074, FHC-102/9…
- Insider · 1 personInsiders: 2 sales (~$46.2M)
What came next
- InsiderOfficer sold ~$3K of ABT shares in the open market
- FDARecall: Amplatzer Amulet Left Atrial Appendage Occluder Model Numbers 1. 9-ACP2-007-016 2. 9-ACP2-007-018 3. 9-ACP2-007-020 4. 9-ACP2-007-022 5. 9-ACP2-010-025 6. 9-AC…
- FDAFDA device clearance: EnSite X EP System
- CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
- CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
- FDAFDA device clearance: Anti-HCV Next
- CongressDisclosed sale of ABT — reported range $50,001 - $100,000
- Company filing · Form 8-K · ResultsReported its results
- FDAFDA device approval: Amplatzer Paraclose PVL Occluder
- InsiderOfficer sold ~$406K of ABT shares in the open market
- Company filing · Form 8-K · Executive changeChanged a top executive or board member
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Abbott Laboratories
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.
Other recent filings by Robert B Ford, CHAIRMAN AND CEO
- SEC Form 4 at Abbott Laboratories (ABT)Aug 27, 2026
- SEC Form 4 at Abbott Laboratories (ABT)Aug 27, 2026
- SEC Form 4 at Abbott Laboratories (ABT)Jan 26, 2026
- SEC Form 4 at Abbott Laboratories (ABT)Feb 7, 2025
The full history of Robert B Ford, CHAIRMAN AND CEO is on the profile page.
How this filing works
Explore the data
Common questions
Which Abbott Laboratories (ABT) insider traded, and how much?
Robert B Ford, CEO at Abbott Laboratories, reported an option exercise of 247K shares. At $59.94.
When did it happen, and when was it made public?
Traded: Aug 25, 2026. Filed: Aug 27, 2026. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Abbott Laboratories recently?
For Abbott Laboratories, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABT page.
Does this mean ABT stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Abbott Laboratories
- SEC Form 13F-HRNov 16, 2026
- SEC Form 4Nov 6, 2026
- SEC Form 144Nov 5, 2026
- House Clerk periodic transaction reportOct 30, 2026
- House Clerk periodic transaction reportOct 27, 2026
- House Clerk periodic transaction reportOct 12, 2026
Everything OQRO holds on this company is on its ABT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
